Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone mechanisms in metabolic syndrome
NCT00579813Phase 4Completed
- Start
- Apr 2005
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pioglitazone in metabolic syndrome, prediabetes and type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoints: Change in Insulin Sensitivity Using FSIGT at 10 weeks, Effects of Pioglitazone on Changes in BMI at 10 weeks and 2 more. Started Apr 2005; status: completed.
02
Drugs
pioglitazone
03
Conditions
metabolic syndromeprediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00579813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00579813.